Neuroceuticals Invests in Theracle, a U.S. VB Company

Neuroceuticals Inc. (Headquarters: Bunkyo-ku, Tokyo; President and CEO: Shinya Miike; hereinafter "NCI"), a medical device venture support company, is pleased to announce that it has invested in the US startup Theracle (Milpitas, California; CEO: Greg Method; hereinafter "Theracle").

[Background of the Investment]

NCI is a medical device development venture support company and incubator/accelerator that supports startups developing medical devices to meet various medical needs. Theracle, our investment, is developing a new catheter-based treatment for inoperable brain tumors and gliomas. Brain tumors can occur in inoperable areas and pose a severe life-threatening prognosis. While previous attempts at treatment have included systemic drug administration, it is a serious disease for which few effective treatments exist due to the inability of drugs to cross the blood-brain barrier (BBB). Pediatric glioma, in particular, is known to develop in children at a young age, but its prognosis is difficult to improve, making it an intractable disease. NCI has been exploring treatments for such diseases. Theracle has developed a specialized catheter-based therapy and is boldly challenging itself to establish a treatment. NCI has now invested in the company to support this mission.

Supporting the Development of Glioma Treatment Devices

[About Theracle]

Theracle is a pre-clinical stage medical technology company developing an implantable drug-delivery platform designed to bypass the blood–brain barrier. The company’s catheter-based system enables direct, repeatable delivery of therapeutics into the brain, maximizing on-target delivery while reducing systemic exposure. Theracle will target applications in oncology, including pediatric gliomas and other CNS cancers, with a broader pipeline focused on neurodegenerative diseases.

[About NCI]

NCI was founded as a medical device development venture company at Kyushu University. However, as we progressed, we realized the significant challenges faced by private venture companies and academic startups in the medical device market in developing and expanding their businesses, leading us to launch a support program for startups in the medical device field.

We have now established our own investment fund for medical device development (Medical Development Support No. 1 Investment Limited Partnership) and are embarking on a hands-on investment business. Our investments include overseas startups, but in these cases, we invest with the aim of domestically manufacturing the products. To date, NCI and our investment fund have invested in and supported 26 startups, two of which have already achieved exits through M&A. We plan to further strengthen our support for domestic and international startups and medical device ventures.

Company Profile

Neuroceuticals, Inc.

Website URL: https://www.nci-md.com/

Head office: 1-28-10 Hongo, Bunkyo-ku, Tokyo, Japan

Theracle LLC.

Home Page URL : https://www.theracle.com/

Location: Milpitas, California